Open Access

Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

  • Michael Ezrokhi1,
  • Shuqin Luo1,
  • Yelena Trubitsyna1 and
  • Anthony H. Cincotta1Email author
Diabetology & Metabolic Syndrome20157:61

https://doi.org/10.1186/s13098-015-0056-x

Received: 24 February 2015

Accepted: 18 June 2015

Published: 4 July 2015

The original article was published in Diabetology & Metabolic Syndrome 2014 6:104

Erratum

After publication of this manuscript [1], we noted errors to the labels of Fig. 7. The Y-axis of panel C was incorrectly labelled as “Plasma Adiponectin, ng/ml” instead of “PEPCK, % of Vehicle”. (Please see a corrected version of Fig. 7 below).
Fig. 7

Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at Ser256 (Panel a), glucose-6-phosphatase (Panel b), and PEPCK (Panel c). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. *Difference is statistically significant; P values are noted under each panel

Notes

Authors’ Affiliations

(1)
VeroScience LLC

Reference

  1. Ezrokhi M, Luo S, Trubitsyna Y, Cincotta AH. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr. 2014;6:104.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Ezrokhi et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement